Good to see you here @Kyriaco. Imagine you have many many more shares than me, but I like the look of this product filling a very key space in the fight against a really nasty cancer. It is biotech though, so SP benefits might be at least 24 months away. Mkt cap on the other hand, if they do have a product that the FDA looks favourably upon, is simply ludicrously cheap. I have to believe there are some US Big Pharma players with an eye on this.
Ann: Cleo Commences US Regulatory Process with FDA, page-8
Add COV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.020(5.41%) |
Mkt cap ! $28.56M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.0¢ | 35.0¢ | $37.21K | 103.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 23560 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 20000 | 1 |
View Market Depth
| Last trade - 15.59pm 02/10/2024 (20 minute delay) ? |
| COV (ASX) Chart |